ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1094

EULAR Points to Consider for the Development, Evaluation and Implementation of Mobile Health Applications for Self-management in Patients with Rheumatic and Musculoskeletal Diseases

Aurelie Najm1, Elena Nikiphorou 2, Marie Kostine 3, Christophe Richez 4, John Pauling 5, Axel Finckh 6, Valentin Ritschl 7, Petra Balazova 8, Simon Stones 9, zoltan Szekanecz 10, Yeliz Prior 11, ANNAMARIA IAGNOCCO 12, Sofia Ramiro 13, Francisca Sivera 14, Maxime Dougados 15, Loreto Carmona 16, Gerd Burmester 17, Dieter Wiek 18, Laure Gossec 19 and Francis Berenbaum 20, 1Nantes University Hospital, Nantes, France, 2King's College London, London, United Kingdom, 3Department of Rheumatology, Bordeaux, France, 4Deprtament of Rheumatology, Bordeaux, France, 5Department of Rheumatology, Royal National Hospital of Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, England, United Kingdom, 6Division of Rheumatology, Geneva University Hospital, Switzerland, Geneva, Switzerland, 7Medical University of Vienna, Vienna, Austria, 8EULAR Young PARE, Zurich, Switzerland, 9University of Leeds, Leeds, United Kingdom, 10University of Debrecen, Debrecen, Hungary, 11Centre for Health Sciences Research, University of Salford, Salford and Mid Cheshire NHS Foundation Trust Hospitals, Crewe, UK, Salford, United Kingdom, 12Academic Rheumatology Centre, Università degli Studi di Torino, TURIN, Italy, 13Leiden University Medical Centre, Leiden, Netherlands, 14Hospital General Universitario de Elda, Elda, Spain, 15Cochin Hospital, Paris, France, 16Instituto de Salud Musculoesquelética - Inmusc., Madrid, Spain, 17Charité—University Medicine Berlin, Berlin, Germany, 18patient research partner, Germany, Germany, Germany, 19Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, 20Sorbonne Université-Inserm CDR Saint-Antoine, AP-HP, Paris, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: , , ,

Session Information

Date: Monday, November 11, 2019

Session Title: Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: In the expanding era of e-health, a wide range of mobile health applications (apps) have become available to enable people with rheumatic and musculoskeletal diseases (RMDs) to better self-manage their health. However, guidance on the development and evaluation of such apps is lacking. The objective of this EULAR task force was to establish points to consider (PtC) for the development, evaluation and implementation of apps for self-management of RMDs.

Methods: A systematic literature review of app content and development strategies was conducted, followed by a qualitative study with six patients and an online survey of people living with RMDs (n=394). Based on these data and expert opinion, the PtC were formulated in a face-to-face meeting in November 2018 by a multidisciplinary TF panel of experts, including patients, from 10 countries. The level of agreement among the panel in regard to each PtC was established by anonymous online voting.

Results: Three overarching principles and 10 PtC were formulated (Table). Out of the 10 PtC, three were related to patient safety (1,5,6), considered as a critical issue by the panel, along with accuracy of information provided by apps. Three were related to relevance of the content and functionalities (2,7,9) and the importance of apps being tailored to the individual needs of people with RMDs. The requirement for transparency around app developers and funding sources (3,4), along with involvement of relevant health professionals were also raised. Ease of app access across ages and abilities was highlighted (8), in addition to considering the cost-benefit of apps from the outset (10). The level of agreement was high (Table).

Conclusion: These PtC provide guidance on important aspects that should be considered for the development of new apps, the quality assessment of existing apps, as well as for further development of existing apps.As part of the dissemination phase, these PtC will be shared with a larger group of health professionals, patients and app developers and for wider consensus.

Figure: The 10 Points to Consider.

Disclosure: A. Najm, None; E. Nikiphorou, AbbVie, 8, Celltrion, 5, 6, Eli Lilly, 8, Eli Lilly and Company, 8, Gilead, 5, 6, Pfizer, 8, Sanofi, 5, 8; M. Kostine, None; C. Richez, None; J. Pauling, Boehringer Ingelheim, 5, Chugai Roche, 9; A. Finckh, Eli-Lilly, 5, 8, Pfizer, 2, 5, 8; V. Ritschl, None; P. Balazova, None; S. Stones, None; z. Szekanecz, None; Y. Prior, None; A. IAGNOCCO, None; S. Ramiro, None; F. Sivera, None; M. Dougados, AbbVie, 2, 5, 8, Amgen, 5, Biogen, 5, BMS, 2, 5, 8, Eli Lilly, 2, 5, 8, Gilead, 2, 5, Janssen, 2, 5, Merck, 2, 5, Merck Inc, 2, 5, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Pfizer Inc, 2, 5, Roche, 2, 5, 8, UCB, 2, 5, 8; L. Carmona, None; G. Burmester, AbbVie, 5, 8, Abbvie, 5, 8, AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma., 5, 8, AbbVie Inc., 5, 8, BMS, 5, 8, Eli Lilly, 5, 8, Eli Lilly and Company, 5, Gilead, 5, 8, Gilead Sciences, Inc., 5, 8, Janssen, 5, 8, Lilly, 5, 8, Merck, 5, 8, Merck Shar & Dohme, 5, 8, MSD, 5, 8, Pfizer, 2, 5, 8, Roche, 2, 5, 8, Roche, Sanofi-Genzyme, 5, 8, Sanofi, 5, 8, UCB, 5, 8, Union Chimique Belge, 2, 5, 8; D. Wiek, None; L. Gossec, Abbvie, 5, AbbVie, 5, Abbvie, Biogen, BMS, Celgene, Lilly, Novartis, Pfizer, SAnofi-Aventis, UCB, 5, Amgen, 5, Biogen, 5, BMS, 2, 5, Celgene, 5, Celgene Corporation, 2, Janssen, 5, Lilly, 2, 5, MSD, 5, Nordic Pharma, 5, Novartis, 5, Pfizer, 2, 5, Sanofi, 5, Sanofi-Aventis, 5, UCB, 5; F. Berenbaum, 4P Pharma, 2.

To cite this abstract in AMA style:

Najm A, Nikiphorou E, Kostine M, Richez C, Pauling J, Finckh A, Ritschl V, Balazova P, Stones S, Szekanecz z, Prior Y, IAGNOCCO A, Ramiro S, Sivera F, Dougados M, Carmona L, Burmester G, Wiek D, Gossec L, Berenbaum F. EULAR Points to Consider for the Development, Evaluation and Implementation of Mobile Health Applications for Self-management in Patients with Rheumatic and Musculoskeletal Diseases [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/eular-points-to-consider-for-the-development-evaluation-and-implementation-of-mobile-health-applications-for-self-management-in-patients-with-rheumatic-and-musculoskeletal-diseases/. Accessed July 1, 2022.

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/eular-points-to-consider-for-the-development-evaluation-and-implementation-of-mobile-health-applications-for-self-management-in-patients-with-rheumatic-and-musculoskeletal-diseases/